Abstract
As an adjunctive treatment in sepsis, patients administered high-dose (0.9g/kg body weight) intravenous immunoglobulin G (IvIgG) did not have a significant survival benefit in a randomized control study (The SBITS study) (1). However, low-dose ivIgG (5g/day 3days) might have some utilities including earlier defervescence and improvements of clinical signs and symptoms (2).
Highlights
As an adjunctive treatment in sepsis, patients administered high-dose (0.9g/kg body weight) intravenous immunoglobulin G (IvIgG) did not have a significant survival benefit in a randomized control study (The SBITS study) (1)
In this retrospective cohort study of patients with severe sepsis and septic shock, we investigated whether low-dose IvIgG was associated with clinically important outcomes including ICU mortality and in-hospital mortality
This study investigated associations between sepsis-related coagulopathy, anticoagulation therapies, and clinical outcomes of 3195 adult patients with severe sepsis and septic shock admitted to ICUs in Japan from January 2011 through December 2013
Summary
In this retrospective cohort study of patients with severe sepsis and septic shock, we investigated whether low-dose IvIgG was associated with clinically important outcomes including ICU mortality and in-hospital mortality
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have